Clinical trials: Diseases of the Urinary System
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Red-Cell Aplasia, Pure
A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins
The purpose of this study is to record the number of participants with chronic renal disease who are receiving treatment with epoetin alfa or other recombinant erythropoietins who develop pure red cell aplasia (PRCA, a rare form…
- Trial name
- NCT00211029
- Volunteers
- 4,670 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Kidney Failure, Chronic
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
The primary objective of the study was to compare the single dose pharmacokinetics of alisporivir in subjects with end stage renal disease (ESRD) on hemodialysis to those of matched healthy subjects.
- Trial name
- NCT01975337
- Testing
- Alisporivir
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Debiopharm International SA
Non Muscle Invasive Bladder Cancer
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have…
- Trial name
- CORE-001 (NCT04387461)
- Testing
- CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
- Where
- 19 sites in United States, South Korea
- Volunteers
- 35 people
- Sponsor
- CG Oncology, Inc.
Urinary Incontinence
Study Evaluating the Efficacy and Safety of Yoni.Fit in Women With Stress Urinary Incontinence
Study to evaluate the safety and effectiveness of Yoni.Fit for the temporary management of stress urinary incontinence (SUI) in women.
- Trial name
- NCT03978741
- Testing
- Yōni.Fit Test Device, Yōni.Fit Comparator Device
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Watkins Conti Products. Inc.
Uremic Pruritus
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session.
- Trial name
- NCT03422653
- Testing
- CR845 0.5 mcg/kg
- Where
- 57 sites in United States
- Volunteers
- 378 people
- Sponsor
- Cara Therapeutics, Inc.
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Stress Urinary Incontinence
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
- Trial name
- NCT04829994
- Testing
- Intervention
- Where
- 8 sites in United States, Austria and 4 more
- Volunteers
- 198 people
- Sponsor
- Ethicon, Inc.
Renal Failure, End Stage Renal Disease
Development, Feasibility Testing and Validation of a Survey Set to Measure Patient-Reported Outcomes Among Hemodialysis Patients in Turkey
Development, feasibility testing and validation of a Survey Set to Measure Patient-Reported Outcomes among Hemodialysis Patients in Turkey: Creating and testing an electronic patient questionnaire that is suitable to measure…
- Trial name
- DOPRO (NCT05441020)
- Testing
- Administration of patient questionnaire
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 173 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Renal Cell Carcinoma
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint…
- Trial name
- NCT04987203
- Testing
- Tivozanib, Nivolumab
- Where
- 139 sites in United States, Argentina and 14 more
- Volunteers
- 343 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Hyperphosphatemia, Chronic Kidney Disease
Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Phosphate binders are crucial to the control of elevated phosphate levels in patients with chronic kidney disease. With the new formulation of granules the pill burden of patients is sought to be reduced.
- Trial name
- OsvaRenNEW (NCT02027662)
- Testing
- Osvaren Granules, Osvaren film-coated tablets
- Where
- 11 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Alport Syndrome, Focal Segmental Glomerulosclerosis
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary…
- Trial name
- NCT05267262
- Testing
- R3R01
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 43 people
- Sponsor
- River 3 Renal Corp.
Atherosclerotic Cardiovascular Disease, Heart Failure
Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management
This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD).
- Conditions
- Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease
- Trial name
- FLARE (NCT07160829)
- Testing
- No treatment given
- Where
- 4 sites in Australia, India and 2 more
- Volunteers
- 608 people
- Sponsor
- Novo Nordisk A/S
Renal Impairment
Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419
The study is a two-center, Phase 1, open-label, single-dose, one-period, four groups, PK study in subjects with various severities of renal impairment and matched healthy controls.
- Trial name
- NCT05412472
- Testing
- GC4419
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Overactive Bladder(OAB)
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers
A randomized, open-label, single-dose, replicate crossover study to compare the pharmacokinetics and safety in healthy adult volunteers following oral administration of JLP-2002
- Trial name
- NCT04914221
- Testing
- JLP-2002, Comparator
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Stress Urinary Incontinence
Autologous Cell Therapy for Female Stress Urinary Incontinence
The Autologous Cell Therapy for Female SUI study is a clinical trial to determine the safety and potential effectiveness of a single dose of 200 million Cook MyoSite Autologous Muscle Derived Cells for treatment of Stress Urinary…
- Trial name
- NCT01008943
- Testing
- Autologous Muscle Derived Cells
- Where
- 2 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Cook MyoSite
Overactive Bladder
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking).
- Trial name
- NCT01868516
- Testing
- dexmecamylamine
- Where
- 125 sites in United States
- Volunteers
- 1,635 people
- Sponsor
- Targacept Inc.